OVARIAN: PLATINUM RESISTANT: CLAUDIN-6 EXPRESSING: CATALINA-2

Study snapshot

Title: TORL Biotherapeutics TORL-1-23 Catalina-2 Ovarian Plt Resistant
Malignancy: Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Stage: Stage 4
Disease setting: Metastatic/Palliative
Line of therapy: 2nd, 3rd, or 4th line
Investigational agent: TORL-1-23
Drug class: Claudin 6 ADC
Principal investigator: Michael Ulm, MD
Sponsor: TORL Biotherapeutics
Path: Epithelial
Randomized: Yes
ClinicalTrials.gov ID: NCT06690775

Histologically or cytologically confirmed diagnosis of advanced (unresectable) or metastatic high grade serous ovarian, primary peritoneal, or fallopian tube cancer. High-grade endometrioid ovarian cancer is permitted, Carcinosarcoma is permitted
Positive CLDN6 expression as per central lab
Platinum resistant disease as per protocol
Patients who are platinum refractory during front-line treatment are excluded
Must have received at least 1 but no more than 3 prior systemic lines of anticancer therapy and for whom single-agent therapy is appropriate as next line
- Adjuvant or neoadjuvant therapy is counted as one line
Measurable disease
ECOG PS 0-1
Must have recovered from acute effects of prior therapy
No clear cell, mucinous, sarcomatous, mixed histology, or low grade, borderline ovarian tumors or non-epithelial ovarian cancers
No prior cancer within 3 years